No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder
Restricted accessLetterFirst published online May, 2015
No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
3.
ArnoldLE, AmanMG, CookAM, WitwerAN, HallKL, ThompsonS, RamadanY: Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry, 45:1196–1205, 2006.
4.
BlockSL, WilliamsD, DonnellyCL, DunnDW, SaylorKE, RubergSJ: Post hoc analysis: Early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. Clin Pediatr (Phila), 49:768–776, 2010.
5.
BusheCJ, SavillNC: Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety. J Psychopharmacol, 28:204–211, 2014.
6.
CharnsilC: Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study. J Atten Disord, 15:684–689, 2011.
7.
ChengJYW, ChenRYL, KoJSN, NgEML: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents – meta-analysis and meta-regression analysis. Psychopharmacology (Berl), 194:197–209, 2007.
8.
Du PaulGJ, AnastopoulosAD, PowerTJ, ReidR, IkedaMJ, McGoeyKE: Parent ratings of attention-deficit/hyperactivity disorder symptoms: Factor structure and normative data. J Psychopathol Behav Assess, 20:3–102, 1998.
9.
Fernández–JaénA, Fernández–MayoralasDM, Calleja–PérezB, Muñoz–JareñoN, Campos Díaz MdelR, López–ArribasS: Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study. J Atten Disord, 17:497–505, 2013.
10.
GadowKD, DeVincentCJ, PomeroyJ: ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord, 36:271–283, 2006.
11.
HarfterkampM, van de Loo–NeusG, MinderaaRB, van der GaagRJ, EscobarR, SchachtA, PamulapatiS, BuitelaarJK, HoekstraPJ: A randomized double-blind study of atomoxetine versus placebo for ADHD symptoms in children with ASD. J Am Acad Child Adolesc Psychiatry, 51:733–741, 2012.
12.
HarfterkampMA, BuitelaarJK, MinderaaRB, Loo-Neus van deG, Gaag van derRJ, HoekstraPJ: Long term treatment with atomoxetine for ADHD symptoms in Children with ASD: An open label extension study. J Child Adolesc Psychopharmacol, 23:1–6, 2013.
13.
HoltmannM, BolteS, PoustkaF: Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: Association with autistic behavior domains and coexisting psychopathology. Psychopathology, 40:172–177, 2007.
14.
JouRJ, HandenBL, HardanAY: Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15:325–330, 2005.
15.
MontoyaA, HervasA, CardoE, ArigasJ, MardomingoMJ, AldaJA, GastaminzaX, Garcia–PolaviejaMJ, GilaberteI, EscobarR: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin, 25:2745–2754, 2009.
16.
NewcornJH, SuttonVK, WeissMD, SumnerCR: Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: The Integrated Data Exploratory Analysis (IDEA) Study. J Am Acad Child Adolesc Psychiatry, 48:511–518, 2009.
RommelseNN, FrankeB, GeurtsHM, HartmanCA, BuitelaarJK: Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry, 19:281–295, 2010.
19.
RutterM, Le CouteurA, LordC: The Autism Diagnostic Interview: Revised (ADI-R). Los Angeles: Western Psychological Services; 2003.
20.
SvanborgP, ThernlundG, GustafssonPA, HagglofB, PooleL, KadesjoB: Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry, 18:240–249, 2009.
21.
TroostPW, SteenhuisMP, Tuynman–QuaHG, KalverdijkLJ, BuitelaarJK, MinderaaRB, HoekstraPJ: Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol, 16:611–619, 2006.
22.
WehmeierPM, DittmannRW, BanaschewskiT, SchachtA: Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology?. J Atten Disord, 18:105–116, 2014.
23.
ZeinerP, GjevikE, WeidleB: Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr, 100:1258–1261, 2011.
